Advertisement

Current Status of PET in the World

  • Seok-Ki Kim
  • Keon W. Kang
  • Myung-Chul Lee
Chapter

Abstract

The concept of fluorodeoxyglucose positron emission tomography (FDG PET) was conceived in the early 1970s by a number of researchers. In August 1976, the first brain and whole-body images were acquired successfully using the initial type of PET scanner optimized for in vivo imaging with positron-emitting radionuclides in humans (Phelps et al. J Nucl Med 16(3):210–24, 1975). This demonstrated the feasibility of the methodology, but it was still far from clinical study.

Keywords

Medical Care System Private Health Insurance Company Medical Cyclotron Public Insurance System Private Insurance System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975;16(3):210–24.PubMedGoogle Scholar
  2. 2.
    Tashiro M, Kubota K, Ito M, Fujimoto T, Yamaguchi K, Sasaki H, Moser E. Clinical PET activities in European and Asia-Oceanian countries. Kaku Igaku. 2001;38(3):255–67.PubMedGoogle Scholar
  3. 3.
    Mansuet M, Grimaldi A, Mangili G, Picchio M, Giovacchini G, Vigano R, Messa C, Fazio F. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis. Eur J Cancer Care. 2009;18:612–9.CrossRefGoogle Scholar
  4. 4.
    van Hooren ACG, Brouwer J, de Bree R, Hoekstra OS, Leemans CR, Uyl-de Groot CA. The cost-effectiveness of 18FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy. Eur Arch Otorhinolaryngol. 2009;266:1441–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Sher DJ, Tishler RB, Annino D, Punglia RS. Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer. Ann Oncol. 15 Oct 2009; 21(5):1072–7Google Scholar
  6. 6.
    Yen RF, Yen MF, Hong RL, Tzen KY, Chien CR, Chen TH. The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma. Acad Radiol. 2009;16(1):54–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Mansueto M, Grimaldi A, Torbica A, Pepe G, Giovacchini G, Messa C, Fazio F. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluoro­deoxyglucose PET and CT comparison. Q J Nucl Med Mol Imag. 2007;51(3):224–34. Epub 1 Jun 2007.Google Scholar
  8. 8.
    Dietlein M, Schicha H. Reimbursement of the PET in oncology in Europe; a questionnaire based survey. Nuklearmedizin. 2003;42:80–5.PubMedGoogle Scholar
  9. 9.
    Krug B, Van Zanten A, Pirson AS, Crott R, Vander Borght T. Activity-based costing evaluation of [18F]-fludeoxyglucose production. Eur J Nucl Med Mol Imaging. 2008;35(1):80–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Nuclear MedicineNational Cancer CenterGyeonggi-doSouth Korea
  2. 2.Department of Nuclear MedicineSeoul National University College of MedicineSeoulSouth Korea
  3. 3.Department of Nuclear MedicineGachon University School of MedicineIncheonSouth Korea

Personalised recommendations